Paper Details

  1. Home
  2. Paper Details

PRISMS: the story of a pivotal clinical trial series in multiple sclerosis.

Author: CohenBruce A, RiveraVictor M

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

The PRISMS study, initiated in 1994 when few disease-modifying drugs existed for multiple sclerosis (MS), has provided up to 8 years of clinical, MRI, safety, and immunogenicity data on subcutaneous interferon (IFN) beta-1a in patients with relapsing-remitting MS. This review collates all the data and discusses future studies involving a new formulation of subcutaneous IFN beta-1a.
Paper Details　
Original Abstract of the Article :
The PRISMS (Prevention of Relapses and disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) study was initiated in 1994, at which time there were few disease-modifying drugs for multiple sclerosis (MS). The PRISMS series of studies has since provided up to 8 years of clinical, magn...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1185/03007991003604018

データ提供：米国国立医学図書館（NLM）

PRISMS: A Beacon of Hope in the Desert of Multiple Sclerosis

Multiple sclerosis (MS) is a challenging desert, where the immune system attacks the myelin sheath of the central nervous system, leading to a range of debilitating symptoms. The PRISMS study, a long-term clinical trial, investigated the effectiveness of subcutaneous interferon beta-1a in patients with relapsing-remitting MS. This study, a beacon of hope in this challenging landscape, provides a valuable resource of data on the safety, efficacy, and immunogenicity of this treatment. The researchers found that interferon beta-1a can effectively prevent relapses and reduce disability in MS patients, offering a potential oasis in this challenging desert.

Interferon Beta-1a: A Potential Oasis in the Desert of MS

The PRISMS study provides strong evidence for the effectiveness of interferon beta-1a in MS. This finding is like discovering a hidden oasis in the desert, a source of relief and hope for patients facing this challenging disease.

Navigating the Uncertainties of MS Treatment

The realm of MS treatment is a complex and often uncertain desert. This study, like a well-worn trail, offers guidance and insights into the potential benefits of interferon beta-1a. Further research is needed to refine our understanding of this treatment and explore its potential for other MS subtypes, but the PRISMS study offers a valuable contribution to our knowledge of MS treatment.

Dr.Camel's Conclusion

The PRISMS study is a testament to the power of long-term clinical research. It's like a long and arduous journey across a vast desert, but the reward is a valuable oasis of knowledge. This study offers hope for those facing MS, illuminating a path towards more effective treatments and a better understanding of this complex disease.

Date :
  1. Date Completed 2010-06-16
  2. Date Revised 2015-11-19
Further Info :

Pubmed ID

20121658

DOI: Digital Object Identifier

10.1185/03007991003604018

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.